---
title: "Tarsus Q2 net sales climb 69% to USD 173.9 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295125303.md"
description: "Tarsus Pharmaceuticals reported Q2 net sales of $173.9 million, a 69% year-over-year increase. The company raised its 2026 net sales guidance to $685-705 million with an expected gross margin of ~83%, while reiterating SG&A and R&D expense targets. Additionally, Tarsus agreed to acquire Alkeus for up to $450 million upfront, comprising 60% cash and 40% stock, plus potential milestones."
datetime: "2026-08-06T15:36:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295125303.md)
  - [en](https://longbridge.com/en/news/295125303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295125303.md)
generator: "portal-rs"
---

# Tarsus Q2 net sales climb 69% to USD 173.9 million

-   Tarsus posted Q2 net sales of USD 173.9 million, up 69% year over year. \* Cash and cash equivalents totaled USD 449.7 million at quarter-end, inclusive of marketable securities. \* Lifted 2026 net sales guidance to USD 685-705 million; gross margin seen at about 83%. \* Reiterated 2026 SG&A expense guidance of USD 545-565 million; R&D expense outlook reiterated at USD 160-210 million. \* Agreed to acquire Alkeus with USD 450 million upfront consideration, split 60% cash and 40% stock; up to USD 350 million in milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TARS.US](https://longbridge.com/en/quote/TARS.US.md)

## Related News & Research

- [Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth | TARS Stock News](https://longbridge.com/en/news/295100037.md)
- [Tarsus to buy Alkeus in deal worth about $450 million upfront](https://longbridge.com/en/news/295097320.md)
- [Workday stock is downgraded after buyout report as growth expectations are 'too optimistic'](https://longbridge.com/en/news/296104750.md)
- [Where will Workday stock be in 5 years if Silver Lake doesn't buy it?](https://longbridge.com/en/news/296091172.md)
- [Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS](https://longbridge.com/en/news/295772808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**